Biopharmaceutical company BioLineRx, has named a new CEO and chief financial officer as the company prepares to shake up its leadership.
Philip Serlin will take over as CEO effective Oct. 10. He will replace Kinnert Savitsky, PhD, who held the position since 2010 and will continue with the company as a scientific advisor through March 2017, the company said in a statement.
BioLineRx, which identifies, in-licenses and develops promising therapeutic candidates, is based out of Israel.
“Phil is an experienced BioLineRx executive, complementing the company's drug development expertise with strategic thinking, as well as business and financial leadership,” said Aharon Schwartz, PhD, chairman of BioLineRx’s board. “The board looks forward to working with Phil to create value for the Company and its shareholders."
Serlin joined the company in 2009 as its CFO and COO. Before joining BioLineRx, Serlin was CFO and COO at Kayote Networks, a telecommunications service company in Passaic, New Jersey. Prior to that, he was the CFO and COO at Tescom Software System Testing, an IT services company.
Mali Zeevi will begin her role as CFO Oct. 10. She joined BioLineRx in 2009 as its director of finance and reporting and has served as its senior director of finance and reporting since 2011.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.